
Sleep Cycle - Stable delivery with an optimistic outlook

Redeye updates its estimates on Sleep Cycle following its Q2 2024 quarterly report, which matched our expectations on sales, while the adjusted EBIT was slightly stronger than anticipated. The main deviation stemmed from 'other income' related to partnerships. The solid currency-adjusted growth, now supported by both ARPU strengthening and subscriber growth, led to a well-deserved increase in the share price.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Sleep Cycle - Stable delivery with an optimistic outlook](#)